

CANNABIS USE: PREVALENCE AND CORRELATES AMONG THE INPATIENTS OF FIRST EPISODE PSYCHOSIS AT COMBINED MILITARY HOSPITAL, LAHORE

Mohsin Aliemuddin, Muhammad Kamran*, Zazar Akbar Ch*, Ahmed Shoaib Tabassum**, Farrukh Salim*

70 Medical Battalion Lahore/National University of Medical Sciences (NUMS) Pakistan, *Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan, **Combined Military Hospital Multan/National University of Medical Sciences (NUMS) Pakistan

ABSTRACT

Objective: To determine the frequency and correlates of cannabis use among the psychiatric inpatients presenting with first episode of psychosis at Combined Military Hospital (CMH), Lahore.

Study Design: Correlational study.

Place and Duration of Study: Combined Military Hospital Lahore, from Nov 2016 to Apr 2017.

Methodology: A total of 88 patients between 18-40 years of age, both male and female, meeting the inclusion and exclusion criteria, presenting to Psychiatry department, CMH Lahore; were enrolled in the study after obtaining their informed consent. Patients were interviewed through Present state examination and the diagnosis was made on the basis of International Classification of Diseases version 10. The data was recorded on the study proforma. Outcome variable was frequency of cannabis abuse among these patients of first episode psychosis. It was compared among various age and gender groups and across educational, marital and residential status of the patient.

Results: The mean age of the patients was 26.59 ± 5.79 years. There were 57 (64.8%) male and 31 (35.2%) female patients in the study group, with a ratio of 1.8 males to 1 female (1.8:1). Cannabis use was found in 25 (28.4%) patients. Statistical analysis revealed non-significant difference in the frequency of cannabis use in age ($p=0.15$), gender ($p=0.69$), educational ($p=0.91$), marital ($p=0.180$) and residential status ($p=0.30$).

Conclusion: Cannabis use is highly correlated and prevalent among the patients presenting with first episode of psychosis.

Keywords: Cannabis use, Psychosis, Substance abuse.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Cannabis, also known as marijuana is a preparation of the Cannabis Indica and is used both as a psychoactive drug and medicine. The main psychoactive part of cannabis is tetrahydrocannabinol (THC), it is one of 483 known compounds in the plant¹. Cannabis is the most popular illicit drug in the world and its prevalence in Pakistan is about 4.0%. The 2013 National Survey on Drug Use reported that more than 4 million people in Pakistan use cannabis on a regular basis, most of whom started using cannabis and other drugs during their teenage years². International Mental health surveys have repeatedly found more substance use, especially cannabis use, among people with a diagnosis of a psychotic disorder^{3,4}. Pros-

pective epidemiological studies have consistently reported that use of cannabis in younger age group increases the risk of schizophrenia-like psychosis; onset age of psychosis is reduced, as well^{5,6}. A popular idea suggested that immature brain might be the reason behind increased susceptibility to adverse effects of cannabis⁷.

Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine, occur commonly in patients with schizophrenia and are associated with increased morbidity and mortality⁸. Data suggests that substance use disorders (especially cannabis use disorders) may also be common in first-episode psychotic patients and appears to be linked to a poor outcome in these patients.

According to a study conducted in USA, 37% patients of first episode psychosis had a lifetime diagnosis of substance use disorder (SUD). 28%

Correspondence: Dr Muhammad Kamran, Dept of Psychiatry, Combined Military Hospital Malir Pakistan

Received: 01 Mar 2019; revised received: 01 Aug 2019; accepted: 07 Aug 2019

out of these had a lifetime cannabis use disorder (CUD) and 21% had a lifetime diagnosis of alcohol use disorder (AUD). Patients with SUD were more likely to be men. Those with CUD had a lower age of onset than those without⁹. Another study conducted in Spain found co-morbid cannabis use of 29% in children and adolescents with first episode psychosis¹⁰. However, limited data is available showing the cannabis use frequency in the patients with first episode psychosis in any mental health facility of Pakistan.

This study will highlight this neglected behavioural problem responsible for excess morbidity and mortality in this vulnerable subgroup of population so that strategies can be devised to help them at clinical as well as institutional/ hospital levels. Cases of psychotic disorder could also be prevented by discouraging cannabis use among vulnerable youths.

METHODOLOGY

This correlational study was conducted in Psychiatry ward, Combined Military Hospital, Lahore from November 2016 to April 2017. Sample size (n=88) was calculated by using the WHO sample size calculator¹¹, including parameters: 95% Confidence Level, 35% Population proportion¹² and Precision to be 10%.

Study was approved from the ethics committee of CMH Lahore (Approval Certificate No.60 /2017). A total of 88 patients between 18-40 years of age, both male and female, who had first episode psychosis meeting the ICD-10 diagnostic criteria were enrolled. They were admitted in Psychiatry ward, CMH Lahore during the study period. Enrollment was carried out through consecutive non-probability sampling, after obtaining informed consent. Data was collected with the help of detailed questionnaire. Patients having history of any previous treatment for psychosis or evidence of psychotic symptoms precipitated by an organic cause were excluded for current study. Presence of psychosis was confirmed by using Present state examination Urdu version and International Classification of Diseases (ICD) version 10. Cannabis use was confirmed by labo-

ratory investigation of urine for THC (Tetrahydrocannabinol). Data was analyzed through SPSS version 21. Numerical variables like age have been presented by mean \pm SD. Categorical variables like gender, cannabis use status, education, marital status and residence have been presented as frequency and percentage. Post-stratification Fishers exact test has been applied taking $p \leq 0.05$ as significant.

RESULTS

Total 88 patients with the age ranged from 18 years to 40 years were included in the study; with a mean age of 26.6 ± 5.8 years. Based on the age, study participants were divided into different age groups. Cannabis users among different age groups along with the percentages are given in figure. There were 57 (64.8%) male and 31 (35.2%) female patients, with a ratio of 1.8 males to 1 fe-




Figure: Frequency of cannabis users among different age groups.

male (1.8:1). It was found that 56 (63.6%) patients belonged to rural whereas 32 (36.4%) patients were from urban/city areas. Majority 47 (53.4%) of the patients were un-married and divorced / widowed were 11 (12.5%) patients. It was found that 31 (35.2%) patients were matriculate while only 14 (15.9%) patients had a graduate degree. Cannabis use was found in 25 (28.4%) patients. Statistically non-significant association ($p=0.15$) was found for age and cannabis use. Moreover, upon stratification no association ($p=0.96$) was found even between different age groups and cannabis use. Cannabis use was reported to be independent of gender with a non-significant asso-

ciation ($p=0.689$). No association was found for educational ($p=0.9$) and marital status ($p=0.18$). It was found that cannabis use was common in both urban and rural areas with non-significant ($p=0.30$) results, as given in table.

mean age of 25.44 ± 6.32 years among British patients presenting with First-Episode Psychosis¹⁸ while relatively higher mean age of 32 ± 7.8 years has been reported by Naeem *et al* 2016 among such patients presenting at Sir Ganga Ram Hospital at Lahore¹⁹.

Table: Association of various effect modifiers with cannabis use.

| Variables | | Cannabis Use | | | p-value |
|--------------------|-------------------------|--------------|----|-------|---------|
| | | Yes | No | % | |
| Gender | Male (n=57) | 17 | 40 | 29.82 | 0.689 |
| | Female (n=31) | 08 | 23 | 25.80 | |
| Educational status | Illiterate (n=25) | 08 | 17 | 32 | 0.91 |
| | Matriculate (n=31) | 09 | 22 | 29 | |
| | Intermediate (n=18) | 05 | 13 | 27.78 | |
| | Graduate (n=14) | 03 | 11 | 21.4 | |
| Marital status | Married (n=47) | 17 | 30 | 36.17 | 0.18 |
| | Unmarried (n=30) | 05 | 25 | 16.67 | |
| | Divorced/Widowed (n=11) | 03 | 08 | 27.27 | |
| Residential status | Rural (n=56) | 18 | 38 | 32.14 | 0.304 |
| | Urban (n=32) | 07 | 25 | 21.87 | |

DISCUSSION

Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine occur commonly in patients with schizophrenia^{13,14}. Prospective epidemiological studies have consistently reported that use of cannabis in younger age group increases the risk of schizophrenia like psychosis and that the age of onset is also reduced¹⁴. The limited available data also suggests that substance use disorders (especially cannabis use disorders) may also be common in first-episode psychotic patients and appear to be associated with poor outcome in these patients¹⁵. The available evidence on frequency of cannabis use in patients with first episode of psychosis varied among various studies in different populations^{5,9,13-15}.

In the present study, the mean age of the patients was 26.59 ± 5.79 years. Naqvi *et al* 2010 reported similar mean age of 24.86 ± 8.83 years among patients presenting with psychosis at The Aga Khan University Hospital, Karachi¹⁶. A similar mean age of 28 ± 8.32 years has been reported by Bianconi *et al* 2015 among British such patient¹⁷. Schoeler *et al* 2016 also reported similar

There were 57 (64.8%) male and 31 (35.2%) female patients in the study group with a male to female ratio of 1.8:1. A similar male predominance among patients with psychosis has also been observed by Bukhsh *et al*²⁰ (2.3:1), Naqvi *et al*¹⁶ (1.4:1) and Naeem *et al*¹⁹ (1.2:1) in Pakistan. Baeza *et al* reported similar male predominance with a male to female ratio of 1.9:1 among Spanish such patients¹⁰. Bhui *et al* also reported similar male predominance with a male to female ratio of 1.6:1 in British such patients²¹. A similar male predominance (m:f, 2.7:1) among Australian such patients was reported by Hides *et al*²² Skinner *et al* however observed a female predominance and reported a male to female ratio of 1:4.6 among Irish such patients²³.

Majority (53.4%) of the patients were unmarried followed by married (34.1%) and divorced/ widowed (12.5%) patients. A similar frequency of un-married (49.2%), married (37.2%) and divorced/widowed patients (13.6%) was reported previously by Naqvi *et al* among such patients presenting at The Agha Khan University Hospital, Karachi¹⁶.

Cannabis use was found in 25 (28.4%) patients. Our observation is similar to that of Green *et al* who reported this frequency to be 28% among American patients with first-episode psychosis⁹. A similar frequency of 29.9% was reported by Verdoux *et al* in France²⁴ while Schoeler observed it to be 31.36% in England¹⁸. Skinner *et al* however observed relatively higher frequency of 40% in Irish such patients²³. A much higher frequency of 51.85% and 70.4% has been reported by Mulè *et al* and Hides *et al* in British and Australian such patients respectively^{22,25}.

The present study is first of its kind in local population and has found the frequency of cannabis use to be 28.4% among patients presenting with first episode of psychosis irrespective of patient's age and gender and educational, marital and residential status. In the light of results of the present study it can be advocated that in future practice patients presenting with first-episode psychosis should be screened for cannabis use. There is also need for community measures to reduce cannabis usage. We observed higher frequency of cannabis use among young, males who were illiterate and un-married or divorced/widowed. We also observed higher frequency of cannabis use in patients coming from rural areas. Though insignificant these differences still mean a lot and necessitate community measures targeting this population.

The strengths of the present study were strict exclusion criteria and stratification of study results for effect modifiers. A strong limitation however was limited sample size of 88 cases. Moreover, it was a single center study and the results of the present study cannot be generalized to whole population. There is need for a multicenter larger study to further establish the magnitude of problem. Such a study is highly recommended in future research.

CONCLUSION

Cannabis use is highly correlated and prevalent among the patients presenting with first episode of psychosis. However, it was not correlated

to patient's age or gender; neither do to his/her educational, marital and residential status.

CONFLICT OF INTEREST

There is no conflict of interest to be declared by any author.

REFERENCES

1. Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. *World Psychiatr* 2016; 15(3): 195-204.
2. Batool S, Manzoor I, Hassnain S, Bajwa A, Abbas M, Mahmood M, et al. Pattern of addiction and its relapse among habitual drug abusers in Lahore, Pakistan. *East Mediterr Health J* 2017; 23(3): 83-89.
3. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *Lancet Psychiatr* 2015; 2(3): 233-38.
4. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull* 2016; 42(5): 1262-69.
5. Donoghue K, Doody GA, Murray RM, Jones PB, Morgan C, Dazzan P, et al. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. *Psychiatry Res* 2014; 215(3): 528-32.
6. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. *Biol Psychiatry* 2016; 79(7): 549-56.
7. Edalati H, Doucet C, Conrod PJ. A developmental social neuroscience model for understanding pathways to substance use disorders during adolescence. *Semin Pediatr Neurol* 2018; 10(2): 345-57.
8. Singh S, Balhara YPS. A review of indian research on co-occurring psychiatric disorders and alcohol use disorders. *Indian J Psychol Med* 2016; 38(1): 10-19.
9. Green AI, Tohen ME, Hamer RM, Strakowski SM, Lieberman JA, Glick I, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. *Schizophrenia Res* 2004; 66(2): 125-35.
10. Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, González-Pinto A, et al. Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPs study). *Schizophrenia Res* 2009; 113(2): 129-37.
11. Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. *Gastroenterology and hepatology from bed to bench*. Winter 2013; 6(1): 14-17.
12. Burns J, Jhazbhay K, Emsley R. Cannabis use predicts shorter duration of untreated psychosis and lower levels of negative symptoms in first-episode psychosis: a South African study. *S Afr J Psychol* 2010; 13(5): 145-60.
13. Iqbal MN, Levin CJ, Levin FR. Treatment for substance use disorder with co-occurring mental illness. *Focus Am Psychiatr Publ* 2019; 17(2): 88-97.
14. Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: A unifying hypothesis. *Schizophrenia Res* 2018; 21(7): 78-85.
15. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review effects

- of cannabis use on human behavior effects of cannabis use on human behavior. *J Am Med Assoc Psychiatry* 2016; 73(3): 292-97.
16. Naqvi I, Murtaza M, Nazir MR, Naqvi HA. Gender difference in age at onset of schizophrenia: A cross sectional study from Pakistan. *J Pak Med Assoc* 2010; 60(10): 886-90.
 17. Bianconi F, Bonomo M, Marconi A, Kolliakou A, Stilo SA, Iyegbe C, et al. Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. *Psychol Med* 2015; 46(5): 995-1003.
 18. Schoeler T, Petros N, Di Forti M, Pingault JB, Klamerus E, Foglia E, et al. Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. *J Am Med Assoc psychiatry* 2016; 73(11): 1173-79.
 19. Naeem F, Habib N, Gul M, Khalid M, Saeed S, Farooq S, et al. A qualitative study to explore patients', carers' and health professionals' views to culturally adapt CBT for psychosis (CBTp) in Pakistan. *Behav Cogn Psychother* 2016; 44(1): 43-55.
 20. Bukhsh A, Ali Z, Tayyab M, Gohar Z, Amjad S. Comparative Evaluation of Side Effects of Typical and Atypical Antipsychotics in Psychotic Patients at Punjab Institute of Mental Health, Lahore, Pakistan. *Bipolar Disorder* 2014; 15(4): 25-29.
 21. Bhui K, Ullrich S, Kallis C, Coid JW. Criminal justice pathways to psychiatric care for psychosis. *Br J Psychiatry* 2015; 207(6): 523-29.
 22. Hides L, Dawe S, Kavanagh D, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. *Br J Psychiatry* 2006; 189(2): 137-43.
 23. Skinner R, Conlon L, Gibbons D, McDonald C. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care. *Acta Psychiatrica Scandinavica* 2011; 123(1): 21-27.
 24. Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J. Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. *Schizophrenia Res* 2003; 59(1): 77-84.
 25. Mulè A, Sideli L, Colli G, Ferraro L, Cascia LAC, Sartorio C, et al. Cannabis consumption and the risk of psychosis. *Evidence-based Psychiatric Care* 2017; 3(1): 25-31.
-